A Novel Serotonin Blocker, Sarpogrelate, Increases Circulating Adiponectin Levels in Diabetic Patients With Arteriosclerosis Obliterans

Persistent Insulin-Sensitizing Effects of Sarpogrelate Hydrochloride, a Serotonin 2A Receptor Antagonist, in Patients With Peripheral Arterial Disease

“…[9][10][11][12] Reduced plasma adiponectin concentration has been found in patients with type 2 diabetes mellitus. 9,11,13,14 These findings suggest that adiponectin might have anti-inflammatory properties and might act as an endogenous modulator for the development of metabolic syndrome and/or IR. Several studies have shown the effects of sarpogrelate on insulin-sensitization and/or increased plasma adiponectin level in diabetic patients with or without nephropathy and vasculopathy.…”

“…Several studies have shown the effects of sarpogrelate on insulin-sensitization and/or increased plasma adiponectin level in diabetic patients with or without nephropathy and vasculopathy. [13][14][15][16][17] These effects of sarpogrelate might contribute not only to risk factor management but also to primary or secondary prevention of ASCDs; however, the insulin-sensitizing effects of sarpogrelate in non-diabetic patients with PAD have not been reported.…”

Roles of Serotonin in Atherothrombosis and Related Diseases

“…In a study of 24 non-diabetic and non-medicated diabetic patients with PAD (Fontaine grades 1 and 2), 300 mg of sarpogrelate decreased insulin resistance at 2 weeks and 3 months after treatment, and increased plasma levels of adiponectin at 3 months after treatment (Kokubu, 2006). Similarly, 300 mg of sarpogrelate increased adiponectin levels at 2 and 3 months after treatment in 8 diabetic patients with ASO (Yamakawa et al, 2003). Treatment with 300 mg of sarpogrelate improved limb ischemic symptoms and decreased interleukin-18 levels in 8 diabetic patients with ASO (Yamakawa et al, 2004).…”

Reduced Albuminuria with Sarpogrelate Is Accompanied by a Decrease in Monocyte Chemoattractant Protein-1 Levels in Type 2 Diabetes

“…In addition, sarpogrelate has been shown to increase plasma adiponectin levels in patients with ASO or diabetes (21,22); however, no previous study examined the relationship between changes in adiponectin and ACR in the action of sarpogrelate, and the mechanisms of the antialbuminuric action of sarpogrelate remains largely unknown. This study is the first to address these issues, by investigating several important factors involved in the pathophysiology of diabetic nephropathy.…”

“…Both thiazolidinedione (TZD) and angiotensin II (AngII) type I receptor blockers (ARB) have been reported to elevate plasma adiponectin levels and to lower MCP-1 levels (16 -20). Administration of sarpogrelate was also reported to elevate plasma adiponectin levels (21,22); however, it is unclear whether this effect is mediated by a common mechanism or by an entirely different mechanism from that of ARB or TZD. This is an intriguing issue, considering that all three drugs (sarpogrelate, ARB, and pioglitazone) reduce urinary albumin excretion; however, no previous studies have investigated this issue clinically.…”